March 9, 2014 | Israeli biomed company BiolineRX held a secondary public offering on Nasdaq. The offering is considered a success, as the company surpassed its goal of $21 million, raising $24 million. The company said that it will use the proceeds for clinical trials of its leukemia and celiac disease treatments.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Clean Energy Company That Mimics The Sun Raises $22M
February 02, 2023

Blood Test Offers Hope For Lung Cancer Patients
February 02, 2023

Israel Opens Its First Satellite Observatory
February 02, 2023

Cloud Data-Securing Startup Raises $30M
February 01, 2023
Facebook comments